202198-91-2Relevant articles and documents
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease
Sharma, Piyoosh,Tripathi, Avanish,Tripathi, Prabhash Nath,Prajapati, Santosh Kumar,Seth, Ankit,Tripathi, Manish Kumar,Srivastava, Pavan,Tiwari, Vinod,Krishnamurthy, Sairam,Shrivastava, Sushant Kumar
, p. 510 - 524 (2019/02/24)
The multitarget-directed strategy offers an effective and promising paradigm to treat the complex neurodegenerative disorder, such as Alzheimer's disease (AD). Herein, a series of N-benzylpiperidine analogs (17–31 and 32–46) were designed and synthesized
ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS
-
Page 61, (2010/02/10)
Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R
A new series of M3 muscarinic antagonists based on the 4-amino-piperidine scaffold
Diouf,Gadeau,Chelle,Gelbcke,Talaga,Christophe,Gillard,Massingham,Guyaux
, p. 2535 - 2539 (2007/10/03)
A series of 4-amino-piperidine containing molecules have been synthesized and structure-affinity relationship toward the M3-muscarinic receptor has been investigated. Chemical modulations provided molecules with Ki for the human M3-R up to 1 nM with variable selectivity (3- to 40-fold) over the human M2-R. Compounds 2 (pA2=8.3, 8.6) demonstrates in vitro on guinea pig bladder and ileal strips potent anticholinergic properties and tissue selectivity.
